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Development of bone marrow (BM) fibrosis and transformation to accelerated/blast 
phase are the main forms of disease progression in myeloproliferative neoplasms (MPN). 
Chronic myeloid leukemia, BCR-ABL1-positive has several well-defined criteria that qualify for a 
diagnosis of accelerated phase (AP) disease according  to the updated WHO Classification 
1
. 
However, the only WHO criterion for diagnosing AP BCR-ABL1 negative MPN is the presence of 
10-19% blasts in bone marrow (BM) and/or peripheral blood (PB) 
1
. Clinical characteristics and 
outcomes of patients with increased blasts falling below the 10% cut-off are not well-known. 
Prognostic schemes such as the International Prognostic Scoring System (IPSS) and the dynamic 
prognostic model (DIPSS), which are used to estimate survival  and risk of leukemic 
transformation in MPN patients, include presence of ≥1% circulating blasts to predict disease 
progression 
2,3
. Other schemes have suggested circulating blast cut-offs of 2 or 3%  
2-7
.  
However, the current WHO classification that forms the basis for the pathology practice does 
not take into account increased blasts when they fall short of 10%.  
Other less common types of disease progression have also been recently reported, but 
their characteristics in relation to AP have not yet been characterized. They include the 
development of persistent absolute monocytosis in patients with established primary 
myelofibrosis (PMF), an occurrence that has been associated with rapid progression and short 
overall survival
8-10
. Absolute monocytosis was also found to be a high-risk prognostic factor in 
patients with polycythemia vera (PV)
11
. In addition, persistent neutrophilic leukocytosis (≥ 13 × 
10⁹/L) occurring around the time of progression to post-polycythemic myelofibrosis (post-PV 
MF) has also been associated with an aggressive course and shorter survival
12
. Elevated 
leukocyte count (≥15 x 10
9
/L) at disease onset or early during the polycythemic phase of PV 
has also been identified as an independent unfavorable prognostic factor
13,14
.   
In this study we searched the files of four large academic medical centers in the 
United States and Italy for cases of BCR-ABL1 negative MPN showing progression-associated 
features. One hundred fourteen patients showed one of the following findings: circulating PB 
(2-19%) and/or BM (≥5-19%) blasts; persistent (≥3 months) neutrophilic leukocytosis (WBC≥15 
x 10
9
/L); or persistent (≥3 months) absolute monocytosis (≥1 x 10
9
/L with monocytes 
accounting for ≥10% of the leukocytes). In the latter two settings, careful review of the 
patients’ clinical data was performed to exclude clinical conditions or treatments known to 
cause reactive neutrophilia or monocytosis. Patients presenting in blast phase (>20% PB or BM 
blasts) were excluded. Cases were also excluded if any of the above progression-associated 
features were already present at disease onset. The original diagnosis in all cases was 
established in accordance the WHO criteria.  
The cases were divided into 4 groups: increased blasts-1 (IB-1) with 2-4% PB blasts 
and <5% BM blasts; increased blasts-2 (IB-2) with 5-9% blasts in BM and/or PB;  accelerated 
phase (AP) with 10-19% blasts in BM and/or PB; and other types of progression (OP) without 
increased blasts. A control group of 93 patients with BCR-ABL1 negative MPN lacking increased 
blasts, monocytosis, or leukocytosis was identified from the archives of Weill Cornell Medicine 
over the same time period. The controls were matched with respect to age and MPN type, 
including PV, essential thrombocytemia (ET), PMF, post-PV MF and post-essential 
thrombocythemia myelofibrosis (post-ET MF).    
The patients’ median age at disease progression was 69 (range 38 to 88) years. There 
were 72 men and 42 women (1.7:1). The initial diagnoses included PV (n=35, 31%), ET (n=9, 
8%), MPN unclassifiable (n=4, 4%), post-PV MF (n=37, 32%), prefibrotic PMF (n=5, 4%), fibrotic 
PMF (n=19, 17%) and post-ET MF (n=5, 4%) (see table 1). The diagnosis of disease progression 
was rendered after a median of 11 (range, <1-40) years of follow-up after patient’s initial 
diagnosis. Ninety-two (79%) patients had increased blasts and were classified as IB-1, IB-2 or AP 
group (see table 1). The OP group included 22 patients with persistent absolute monocytosis or 
neutrophilic leukocytosis. In addition to defined signs of progression above, the most common 
additional clinical signs at the time of disease progression were increasing symptomatic 
splenomegaly (76%), anemia (35%), and decreasing platelet count (15%).  
Groups IB-1 and IB-2 comprised 16 cases of PV, 4 ET, 2 MPN-U and 22 PMF (see figure 
1A). Myelofibrosis (MF 2-3) was significantly more prevalent in the IB-1 group (85%) compared 
to the IB-2 group (50%) (p=0.0017), AP group (67%, p=0.005) and OP group (36%, p<0.0001). 
Morphologic dysplasia was frequently seen (Table 1), and was overall similar in all groups. The 
AP group comprised 2 cases of PV, 1 ET, 2 MPN-U and 10 PMF/Post-ET MF/Post-PV MF (see 
Figure 1B). The OP group comprised 12 cases of PV, 2 ET and 8 PMF/Post-ET MF/Post-PV MF. 
Twelve patients had neutrophilia (8 PV, 2 post PV MF, 1 ET, 1 post ET MF) (see Figure 1C) with 
the median WBC of 58 (range, 18.5 to 151 x 10⁹/L) and a median neutrophil count of 81% 
(range, 62-94%). None of these patients had monocytosis. The remaining OP patients (4 PMF 
and 1 ET) had persistent absolute monocytosis (see Figure 1D) with the median WBC of 52 x 
10⁹/L (range, 16.8-120 x 10⁹/L); a median absolute monocyte count of 10.5 x 10⁹/L (range, 2.0-
38.4) and a median monocyte percentage of 30% (range, 11-81%).  
At the time of disease progression, the most common cytogenetic abnormalities 
included a complex karyotype, deletion 20q, abnormalities of chromosome 7, trisomy 8 and 
trisomy 9. Abnormal karyotype was more frequent in groups with increased blasts, but this 
association was not statistically significant (p=0.15).  Complex karyotype was more frequent in 
the AP group compared to IB-1 (p=0.02). Molecular analysis demonstrated that 80% of the 
patients had JAK2 mutations, while 13% had CALR and 1% had MPL mutations (see table 1). The 
mean JAK2 variant allele frequency (VAF) at the time of progression was 75% (range, 3-99%).  
The JAK2 VAF was generally stable in each patient, regardless of disease phase or the presence 
of progression. 30 patients underwent next generation sequencing. Additional mutations were 
present in all groups (75% IB1, 40% IB2, 75% OP and 100% AP patients) and included TET2 (40% 
of all cases), followed by ASXL1 and DNMT3A in 17% each, EZH2 KRAS and CBL in 10%, as well 
as many other mutations in a smaller number of patients. There was no relationship between 
the type of mutation and the patient group or clinical outcome, with the caveat that the study 
size was small. Further studies are needed to clarify these findings. 
We compared the cases to a matched control group of MPNs with a similar follow-up 
duration (median 105.8 months versus 88.5 months, respectively; p=0.07). Although the control 
cases were matched to the disease subtypes of the progression cases, there was a trend for 
younger age, female gender, and shorter observation period in the controls compared to the 
cases (supplemental Table 1); this may be related to the longer clinical course of the MPN 
patients who progressed. In the study group, 47/113 (42%) patients died of disease (median 11 
months, range of 1-63 months following disease progression), compared to 19/93 (20%) control 
patients. Patients in group IB-2, had a significantly worse overall survival (OS) than control 
patients (p=0.023, Figure 1A), while patients in group IB-1 had similar OS to controls (Figure 
1A). Patients in the OP group had a significantly shorter OS compared to controls (p<0.0001) 
and the IB-1 group (p=0.023), but similar OS to the AP group (p=0.85, Figure 1B and C).  As 
expected, AP patients had significantly shorter OS than controls (p<0.0001), and combined IB-
1/IB-2 patients (p=0.0038, Figure 1D). The presence of myelofibrosis or specific MPN type did 
not affect patient survival in this cohort (data not shown).   
In conclusion, our results validate the current WHO cut-off of 10% blasts that defines AP 
in MPNs 
15
. We found that the overall survival of MPN patients with 2-4% PB blasts was similar 
to matched control MPN patients without increased blasts. However, patients with 5-9% BM or 
PB blasts had intermediate survival between MPN AP cases and the MPN controls. Thus, we 
propose that MPN patients developing 5-9% PB or BM blasts, persistent neutrophilic 
leukocytosis, or absolute monocytosis experience worse outcomes than patients in chronic 
phase MPN and warrant closer clinical follow-up and possibly earlier therapeutic interventions. 
These new parameters should be considered for future inclusion among pathologic criteria for 
diagnosing disease progression in MPN and in future modifications to dynamic MPN scoring 
systems. 
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Table 1. The summary of clinicopathologic and molecular characteristics of the patients 
(n=114). 
 IB-1 (n=33) IB-2 (n=44) AP group (n=15) OP group (n=22) 
     
Myelofibrosis MF2-3 28 (85%) 22 (50%) 10 (67%) 8 (36%) 
WBC, median (range) x 
10⁹/L 
18 (2.1-81.3) 23 (1.1-305) 20 (5.2-53.5) 40 (2.1-151) 
Hb, median (range) g/dL 10.2 (7.1-14.2) 10.8 (7.3-15) 9.6 (6.1-13.2) 11.1 (8.1-15.4) 
Plt, median (range) x 10⁹/L 278 (56-753) 319 (10-1759) 258 (20-1291) 612 (26-1632) 
PB blasts, % median (range) 3 (2-4) 3 (0-9) 8 (0-15) <1 (0-1) 
BM blasts, % median 
(range) 
3 (1-4) 5 (1-9) 10 (4-19) 2 (0-4) 
Dysgranulopoiesis 24% 43% 71% 37% 
Dyserythropoiesis 44% 56% 43% 19% 
Abnormal karyotype 41% 48% 52% 42% 
Complex karyotype 7% 15% 19% 16% 
JAK2 mutation present 84% 86% 67% 44% 
CALR mutation present 16% 5% 19% 7% 
MPL mutation present 0 0 0 0 
IB-1, increased blasts (<5% blasts); IB-2, increased blasts (5-9% blasts); AP, accelerated phase; 
OP, other types of progression (no increased blasts), Chronic MPN, includes cases of ET, PV, 
MPN, U without evidence of marrow fibrosis; Hb, hemoglobin; Plt, platelet 
 
 
 
 
 
 
 
 
 
 
FIGURE LEGENDS. 
Figure 1. Morphologic characteristics of the bone marrow biopsy findings. A. Patient with post-
polycythemia myelofibrosis who developed 7% bone marrow blasts (group IB-2). CD34 
highlights an increase in blasts (insert). B. Patient with post-polycythemia myelofibrosis who 
developed accelerated phase (group AP). C. Patient with polycythemia vera with neutrophilic 
progression (group OP). D. Patient with primary myelofibrosis with monocytic progression 
(group OP). 
Figure 2. Survival analysis in patients with disease progression. A, Comparison between groups 
IB-1 (green), IB-2 (blue) and the control patients (red) shows a significantly worse survival for 
patients in group IB-2 (5-9% blasts) compared to both group IB-1 and controls. Conversely, 
there is no significant difference in survival between controls and IB-1 patients (p=0.24). B. The 
OP group patients (purple) have significantly shorter survival than controls (red) (p<0.0001) and 
the IB-1 group (P=0.023), but similar survival to AP group (p=0.85). C, Comparison between IB-1 
and IB-2 groups (combined, in red) and OP group (in blue) shows that patients with alternative 
forms of progression have outcomes similar to those with excess blasts with a trend toward 
even poorer survival. D, Comparison between AP group (red) and the IB-1 and IB-2 group 
patients shows a significant difference in survival. 
 
 
 


